Oxurion (formerly known as ThromboGenics) is a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye. The Company has built a diverse portfolio of disease-modifying therapies, including treatments for diabetic eye disease, a leading cause of blindness in people of working age worldwide.
Market capitalization (10-Nov-2021)
Closing stock price (10-Nov-2021)
Oxurion has 1.2k Twitter Followers. The number of followers has increased 0.7% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was Oxurion founded?
Oxurion was founded in 1991.
Who are Oxurion key executives?
Oxurion's key executives are Adrienne Graves, David Guyer and Emmanuèle Attout.
How many employees does Oxurion have?
Oxurion has 78 employees.
Who are Oxurion competitors?
Competitors of Oxurion include Olainfarm, pixon and Celyad.
Where is Oxurion headquarters?
Oxurion headquarters is located at 1 Gaston Geenslaan, Leuven.
Where are Oxurion offices?
Oxurion has offices in Leuven, Dublin 8 and Dublin.
How many offices does Oxurion have?
Oxurion has 3 offices.
Receive alerts for 300+ data fields across thousands of companies